BioMarin Pharma (BMRN) Tops Q4 EPS

BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.00, which may not compare to the analyst estimate of ($0.06). Revenue for the quarter came in at $537.5 million versus the consensus estimate of $537.62 million.

GUIDANCE:

BioMarin Pharma sees FY2023 EPS of $1.80-$2.05, versus the consensus of $1.61. BioMarin Pharma sees FY2023 revenue of $2.375-2.5 billion, versus the consensus of $2.58 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $111 at Barclays
• XP Inc eyes US banking license as next business step